+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression



Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression



Oncology Reports 14(2): 337-343



Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) are well-investigated molecules and the focus of many breast cancer therapies. There is a group of breast cancers lacking ER and HER2, but it is not fully understood. Treatment for these patients is limited to cytotoxic chemotherapy. The purpose of present study is to examine ER(-)/HER2(-) breast cancers, with a particular focus on epidermal growth factor receptor (EGFR).

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 012052262

Download citation: RISBibTeXText

PMID: 16012712


Related references

Human epidermal growth factor receptor 1 (EGFR) expression was not associated with gene amplification but intimately assoclated with HER2 gene amplification and protein expression in tissue microarray of clinical breast cancers. European Journal of Cancer Supplements 4(2): 122-123, 2006

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology 18(8): 1027-1033, 2005

Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer 19(4): 309-314, 2013

Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anti-Cancer Drugs 18(7): 835-837, 2007

Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Molecular Endocrinology 1(3): 216-223, 1987

Research progress on significance of androgen receptor and epidermal growth factor receptor expression in estrogen receptor-negative and progesterone receptor-negative breast cancer. Zhonghua Bing Li Xue Za Zhi 47(3): 226-229, 2018

Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients. Diagnostic Pathology 6: 57, 2011

Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Science 107(4): 491-498, 2016

Expression of estrogen receptors in estrogen receptor-negative human breast carcinoma cells: modulation of epidermal growth factor-receptor (EGF-R) and transforming growth factor alpha (TGF alpha) gene expression. Journal of Cellular Biochemistry 54(3): 289-298, 1994

Kinase-negative mutant epidermal growth factor receptor (EGFR) expression during embryonal stem cell differentiation favours EGFR-independent lineages. Development 122(10): 3331-3342, 1996

Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor. Molecular and Clinical Oncology 4(4): 648-654, 2016

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. Bmc Cancer 11: 31, 2011

Expression of epidermal growth factor receptor and its messenger rna in estrogen receptor negative human breast cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 27: 219, 1986

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. Journal of Clinical Oncology 27(24): 3908-3915, 2009

Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Clinical Breast Cancer 17(1): 41-47, 2016